Gabapentin "Pfizer"

Primær information

  • Handelsnavn:
  • Gabapentin "Pfizer" 100 mg kapsler, hårde
  • Dosering:
  • 100 mg
  • Lægemiddelform:
  • kapsler, hårde
  • Brugt til:
  • Mennesker
  • Medicin typen:
  • Allopatiske stof

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Gabapentin "Pfizer" 100 mg kapsler, hårde
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • Lægemiddelstyrelsen - Danish Medicines Agency
  • Autorisationsnummer:
  • 46892
  • Sidste ændring:
  • 01-02-2018
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.

13-7-2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, Due to Infusion Reactions

Hospira, Inc., a Pfizer company, is voluntarily recalling 8 lots of Hospira’s Daptomycin for Injection 500 mg, Lyophilized Powder For Solution, Single Dose Vial (NDC 0409-0106-01) to the Hospital/Retail level. The product is being recalled due to adverse event reports indicative of infusion reactions.

FDA - U.S. Food and Drug Administration

4-6-2018

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

FDA - U.S. Food and Drug Administration

1-6-2018

Demulen 30 birth control pills: Packages containing broken or chipped pills

Demulen 30 birth control pills: Packages containing broken or chipped pills

Pfizer Canada Inc. has notified Health Canada that it has received complaints of broken or chipped pills involving Demulen 30, a prescription birth control pill. Health Canada has previously communicated on similar issues involving two other brands of birth control pills. Health Canada continues to remind women to check their packages of birth control pills and to report problems if they see them. If you notice anything unusual in the package, such as missing or damaged pills, you should return the packa...

Health Canada

15-5-2018

May 7, 2018: Abingdon Nurse Practitioner Pleads Guilty to Conspiring to Illegally Prescribe Buprenorphine, Clonazepam, and Gabapentin at Substance Abuse Treatment Program

May 7, 2018: Abingdon Nurse Practitioner Pleads Guilty to Conspiring to Illegally Prescribe Buprenorphine, Clonazepam, and Gabapentin at Substance Abuse Treatment Program

May 7, 2018: Abingdon Nurse Practitioner Pleads Guilty to Conspiring to Illegally Prescribe Buprenorphine, Clonazepam, and Gabapentin at Substance Abuse Treatment Program

FDA - U.S. Food and Drug Administration

10-8-2018

Torisel (Pfizer Europe MA EEIG)

Torisel (Pfizer Europe MA EEIG)

Torisel (Active substance: Temsirolimus) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5521 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/799/T/71

Europe -DG Health and Food Safety

10-8-2018

Bortezomib Hospira (Pfizer Europe MA EEIG)

Bortezomib Hospira (Pfizer Europe MA EEIG)

Bortezomib Hospira (Active substance: bortezomib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5515 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4207/T/10

Europe -DG Health and Food Safety

7-8-2018

Vyndaqel (Pfizer Europe MA EEIG)

Vyndaqel (Pfizer Europe MA EEIG)

Vyndaqel (Active substance: tafamidis) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5427 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2294/T/45

Europe -DG Health and Food Safety

7-8-2018

Inlyta (Pfizer Europe MA EEIG)

Inlyta (Pfizer Europe MA EEIG)

Inlyta (Active substance: Axitinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5429 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2406/T/24

Europe -DG Health and Food Safety

6-8-2018

Rapamune (Pfizer Limited)

Rapamune (Pfizer Limited)

Rapamune (Active substance: sirolimus) - Centralised - 2-Monthly update - Commission Decision (2018)5384 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/273/II/164

Europe -DG Health and Food Safety

6-8-2018

DUAVIVE (Pfizer Europe MA EEIG)

DUAVIVE (Pfizer Europe MA EEIG)

DUAVIVE (Active substance: oestrogens conjugated / bazedoxifene) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5379 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2314/T/18

Europe -DG Health and Food Safety

6-8-2018

Conbriza (Pfizer Europe MA EEIG)

Conbriza (Pfizer Europe MA EEIG)

Conbriza (Active substance: bazedoxifene) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5388 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/913/T/47

Europe -DG Health and Food Safety

6-8-2018

Bosulif (Pfizer Europe MA EEIG)

Bosulif (Pfizer Europe MA EEIG)

Bosulif (Active substance: Bosutinib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5372 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2373/T/32

Europe -DG Health and Food Safety

6-8-2018

ReFacto AF (Pfizer Europe MA EEIG)

ReFacto AF (Pfizer Europe MA EEIG)

ReFacto AF (Active substance: Moroctocog alfa ) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5374 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/232/T/146

Europe -DG Health and Food Safety

1-8-2018

Toviaz (Pfizer Europe MA EEIG)

Toviaz (Pfizer Europe MA EEIG)

Toviaz (Active substance: fesoterodine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5225 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/723/T/52

Europe -DG Health and Food Safety

1-8-2018

Lyrica (Pfizer Europe MA EEIG)

Lyrica (Pfizer Europe MA EEIG)

Lyrica (Active substance: pregabalin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5223 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/546/T/95

Europe -DG Health and Food Safety

1-8-2018

Viagra (Pfizer Europe MA EEIG)

Viagra (Pfizer Europe MA EEIG)

Viagra (Active substance: sildenafil) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5203 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/202/T/98

Europe -DG Health and Food Safety

1-8-2018

IBRANCE (Pfizer Europe MA EEIG)

IBRANCE (Pfizer Europe MA EEIG)

IBRANCE (Active substance: palbociclib) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5224 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3853/T/14

Europe -DG Health and Food Safety

1-8-2018

Revatio (Pfizer Europe MA EEIG)

Revatio (Pfizer Europe MA EEIG)

Revatio (Active substance: sildenafil) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5221 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/638/T/82

Europe -DG Health and Food Safety

1-8-2018

Enbrel (Pfizer Europe MA EEIG)

Enbrel (Pfizer Europe MA EEIG)

Enbrel (Active substance: Etanercept) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5195 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/262/T/222

Europe -DG Health and Food Safety

1-8-2018

Inflectra (Pfizer Europe MA EEIG)

Inflectra (Pfizer Europe MA EEIG)

Inflectra (Active substance: Infliximab) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5206 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2778/T/64

Europe -DG Health and Food Safety

1-8-2018

Champix (Pfizer Europe MA EEIG)

Champix (Pfizer Europe MA EEIG)

Champix (Active substance: varenicline tartrate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5197 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/699/T/71

Europe -DG Health and Food Safety

1-8-2018

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Pfizer Europe MA EEIG)

Nimenrix (Active substance: Meningococcal group A, C, W-135 and Y conjugate vaccine) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5220 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2226/T/80

Europe -DG Health and Food Safety

1-8-2018

Mylotarg (Pfizer Europe MA EEIG)

Mylotarg (Pfizer Europe MA EEIG)

Mylotarg (Active substance: gemtuzumab ozogamicin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5233 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4204/T/1

Europe -DG Health and Food Safety

1-8-2018

Pregabalin Pfizer (Pfizer Limited)

Pregabalin Pfizer (Pfizer Limited)

Pregabalin Pfizer (Active substance: pregabalin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5234 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3880/T/24

Europe -DG Health and Food Safety

1-8-2018

Tygacil (Pfizer Europe MA EEIG)

Tygacil (Pfizer Europe MA EEIG)

Tygacil (Active substance: Tigecycline) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5218 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/644/T/104

Europe -DG Health and Food Safety

30-7-2018

Besponsa (Pfizer Europe MA EEIG)

Besponsa (Pfizer Europe MA EEIG)

Besponsa (Active substance: inotuzumab ozogamicin) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5104 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4119/T/7

Europe -DG Health and Food Safety

30-7-2018

Trazimera (Pfizer Europe MA EEIG)

Trazimera (Pfizer Europe MA EEIG)

Trazimera (Active substance: trastuzumab) - Centralised - Authorisation - Commission Decision (2018)5095 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4463

Europe -DG Health and Food Safety

27-7-2018

EU/3/13/1127 (Pfizer Europe MA EEIG)

EU/3/13/1127 (Pfizer Europe MA EEIG)

EU/3/13/1127 (Active substance: Inotuzumab ozogamicin) - Transfer of orphan designation - Commission Decision (2018)5046 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/194/12/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/06/401 (Pfizer Europe MA EEIG)

EU/3/06/401 (Pfizer Europe MA EEIG)

EU/3/06/401 (Active substance: N-methyl D-(2,3,4,5,6-pentahydroxy-hexyl)-ammonium; 2-(3,5-dichloro-phenyl)-benzoxazole-6-carboxylate) - Transfer of orphan designation - Commission Decision (2018)5038 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/032/06/T/03

Europe -DG Health and Food Safety

27-7-2018

EU/3/00/005 (Pfizer Europe MA EEIG)

EU/3/00/005 (Pfizer Europe MA EEIG)

EU/3/00/005 (Active substance: Gemtuzumab Ozogamicin) - Transfer of orphan designation - Commission Decision (2018)5037 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/022/00/T/02

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/1066 (Pfizer Europe MA EEIG)

EU/3/12/1066 (Pfizer Europe MA EEIG)

EU/3/12/1066 (Active substance: tafamidis) - Transfer of orphan designation - Commission Decision (2018)5066 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/115/12/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/06/420 (Pfizer Europe MA EEIG)

EU/3/06/420 (Pfizer Europe MA EEIG)

EU/3/06/420 (Active substance: Temsirolimus) - Transfer of orphan designation - Commission Decision (2018)5065 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/058/06/T/02

Europe -DG Health and Food Safety

27-6-2018

Nexium Control (Pfizer Consumer Healthcare Limited)

Nexium Control (Pfizer Consumer Healthcare Limited)

Nexium Control (Active substance: esomeprazole) - Centralised - Renewal - Commission Decision (2018) 4111 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2618/R/21

Europe -DG Health and Food Safety

25-6-2018

Xeljanz (Pfizer Limited)

Xeljanz (Pfizer Limited)

Xeljanz (Active substance: Tofacitinib) - Centralised - Yearly update - Commission Decision (2018)4023 of Mon, 25 Jun 2018

Europe -DG Health and Food Safety

11-6-2018

BeneFIX (Pfizer Limited)

BeneFIX (Pfizer Limited)

BeneFIX (Active substance: Nonacog alfa) - Centralised - Yearly update - Commission Decision (2018)3778 of Mon, 11 Jun 2018

Europe -DG Health and Food Safety

4-6-2018

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Active substance: apixaban) - Centralised - 2-Monthly update - Commission Decision (2018)3616 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2148/II/50

Europe -DG Health and Food Safety

4-6-2018

Champix (Pfizer Limited)

Champix (Pfizer Limited)

Champix (Active substance: varenicline tartrate) - Centralised - Yearly update - Commission Decision (2018)3620 of Mon, 04 Jun 2018

Europe -DG Health and Food Safety

24-5-2018

Bosulif (Pfizer Limited)

Bosulif (Pfizer Limited)

Bosulif (Active substance: Bosutinib) - Centralised - Variation - Commission Decision (2018)3269 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2373/X/26

Europe -DG Health and Food Safety

15-5-2018

LIFMIOR (Pfizer Limited)

LIFMIOR (Pfizer Limited)

LIFMIOR (Active substance: etanercept) - Centralised - Yearly update - Commission Decision (2018)3004 of Tue, 15 May 2018

Europe -DG Health and Food Safety

23-4-2018

Mylotarg (Pfizer Limited)

Mylotarg (Pfizer Limited)

Mylotarg (Active substance: gemtuzumab ozogamicin) - New authorisation - Commission Decision (2018)2504 of Mon, 23 Apr 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4204

Europe -DG Health and Food Safety